|
Rick, I agree with your assessment that Mr. Alberts will probably serve PRLN more as a consultant/advisor than as a research scientist. While he was originally a research chemist, his years at Merck were spent directing the research of others. In any event, he is retired now, and thus not likely to take up the resarch mantle of Dr. Babish. His considerable experience directing research teams is unlikely to be in demand at PRLN, where the research "team" was just Dr. Babish himself. Maybe they hired Mr. Alberts to set up a research team? If so, this would mean that PRLN will have to become a larger entity and that much money would have to be spent to change the focus of the company from discovery to development. Mr. Alberts' experience with Merck was oriented towards developing standard pharmacologics "from start to finish". Does this mean that PRLN intends to follow the same model now? The fact is that PRLN decided to market AndroVir&Car as nutritional supplements is because they could not afford either the dollars or years involved to become a drug developer. Thus, I believe that the Mr. Alberts was hired quickly, mainly for cosmetic reasons, in hopes of soothing serious doubts stemming from the unexpected resignation of Dr. Babish, and to give PRLN some semblance of credibility within the research community. But I don't think that PRLN intends for Mr. Alberts to take over the research functions of Dr. Babish because he is retired, is not a close match for Dr. Babish and is not an employee but a consultant. Neither do I see Mr. Alberts' background as being particularly relevant to what PRLN needs most for its immediate, short term survival, namely help in MARKETING of Androvir and Androcar as NUTRITIONAL SUPPLEMENTS. Best regards to all, Bill. |
